← Back to Search

Kinase Inhibitor

Sorafenib plus VT-122 for Hepatocellular Carcinoma

Phase 2
Waitlist Available
Research Sponsored by Vicus Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

Study Summary

The purpose of this study is to determine if VT-122 provides a clinical benefit when added to Sorafenib in patients with advanced hepatocellular carcinoma (HCC).

Eligible Conditions
  • Hepatocellular Carcinoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
failure free survival
Secondary outcome measures
clinical benefit response

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Sorafenib plus VT-122Experimental Treatment2 Interventions
Group II: Sorafenib with placeboPlacebo Group2 Interventions
Participants randomized to the Control Arm (sorafenib with placebo) receive sorafenib as the standard of care, and placebo for the same periods as participants randomized to the Treatment Arm (sorafenib plus VT-122). Participants randomized to the Control Arm will undergo the same visits and procedures as would the participants randomized to the Treatment Arm.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Sorafenib
FDA approved

Find a Location

Who is running the clinical trial?

Vicus TherapeuticsLead Sponsor
2 Previous Clinical Trials
72 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)
2010. "Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01265576.
All > Hcc > Hepatocellular Carcinoma
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top